BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 µM) or HDAC2 (IC50 of 1.34 µM). BRD3308 suppresses pancreatic beta-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].
Molekulargewicht:
287.29
Reinheit:
98.34
CAS Nummer:
[1550053-02-5]
Formel:
C15H14FN3O2
Target-Kategorie:
Apoptosis,HDAC,HIV
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
